High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Por:
Lahuerta, JJ, San-Miguel, J, Jiménez-Ubieto, A, Alonso, R, Paiva, B, Puig, N, Cedena, MT, Gutierrez, NC, Calasanz, MJ, Guijarro, MF, Tamayo, RR, Rocafiguera, AO, Blanchard, MJ, Cruz, EC, Martínez-Martínez, R, Bargay, J, Balari, AS, de la Rubia, J, García, MTH, Cabañas, V, Montero, FC, Bernal, LP, Montes, YG, Martínez-Lopez, J, Rodriguez-Otero, P, Krisnik, I, Arguiñano, JM, García, MEG, Ocio, EM, de la Cruz, J, Mateos, MV, Rosiñol, L, Bladé, J and Spanish Myeloma Grp
Publicada:
9 oct 2025
Ahead of Print:
1 oct 2025
Resumen:
In retrospective studies, autologous stem cell transplantation (ASCT) conditioning with intravenous busulfan and melphalan (BUMEL) led to longer progression-free survival (PFS) than melphalan alone (MEL200). We compared long-term outcomes of BUMEL vs MEL200 in the context of intensified bortezomib, lenalidomide, and dexamethasone (VRD) induction and consolidation therapies. GEM12 was a phase 3 trial for patients with newly diagnosed multiple myeloma (NDMM) eligible for ASCT including 6 reinforced VRD cycles followed by ASCT conditioned with BUMEL or MEL200 and 2 VRD consolidation cycles. The primary end point was PFS. Subgroup analyses were based on International Staging System (ISS) stages and high-risk genetic abnormalities. Patients were randomized with an open-label 2 x 2 factorial design and 1:1:1:1 allocation ratio to ensure the balance between the GEM12 and the subsequent phase 3 GEM14 trial. Between 2013 and 2015, 458 patients were randomized (BUMEL, n = 230; MEL200, n = 228). The 10-6 MRDnegative rate was 63%, 68% for BUMEL vs 58% for MEL200 (odds ratio, 1.51; P = .035). The median PFS was 89 months for BUMEL and 73.1 for MEL200 (hazard ratio, 0.89 [95% confidence interval, 0.70-1.14]; P = .3). BUMEL showed benefit for patients with ISS stages II or III, t(14;16), and del(1p). For subcohorts ISS stages II or III treated with BUMEL and ISS I treated with MEL200 the median PFS was 96.5 months (95% confidence interval, 76 to not estimable). No safety concerns were observed. After a median follow-up of 8.4 years, GEM2012 demonstrated one of the longest PFS values reported in patients with NDMM, with significant differences favoring BUMEL in advanced ISS stages. The trial was registered at www.ClinicalTrials.gov as #NCT01916252 and at European Union Drug Regulating Authorities Clinical Trials as EudraCT 2012-005683-10.
Filiaciones:
San-Miguel, J:
Inst Invest Hosp Univ 12 Octubre, Hematol Dept, Madrid, Spain
Jiménez-Ubieto, A:
Univ Navarra, Inst Res Neurol Disabil Castilla La Mancha, Ctr Appl Med Res,Hematol Dept, Ctr Biomed Res Canc Network,Canc Ctr Clin, Pamplona, Spain
Alonso, R:
Univ Navarra, Inst Res Neurol Disabil Castilla La Mancha, Ctr Appl Med Res,Hematol Dept, Ctr Biomed Res Canc Network,Canc Ctr Clin, Pamplona, Spain
Paiva, B:
Inst Invest Hosp Univ 12 Octubre, Hematol Dept, Madrid, Spain
Puig, N:
Hosp Univ 12 Octubre, Hematol Dept, Madrid, Spain
Cedena, MT:
Hosp Univ Salamanca, Hematol Dept, Salamanca, Spain
Gutierrez, NC:
Hosp Univ 12 Octubre, Hematol Dept, Inst Invest Biomed i 12, Madrid, Spain
Calasanz, MJ:
Univ Salamanca, Inst Mol & Cellular Biol Canc,Hematol Dept, Canc Res Ctr,Ctr Biomed Res Canc Network, Inst Biomed Res Salamanca,Hosp Univ Salamanca, Salamanca, Spain
Guijarro, MF:
Clin Univ Navarra, Genet Dept, CIMALAB Diagnost, Pamplona, Spain
Tamayo, RR:
Hosp Univ 12 Octubre, Genet Dept, Madrid, Spain
:
Hosp Univ Virgen de las Nieves, Hematol Dept, Granada, Spain
Blanchard, MJ:
Hosp Germans Trias i Pujol, Inst Catala Oncol, Hematol Dept, Badalona, Spain
Hosp Germans Trias i Pujol, Inst Josep Carreras, Badalona, Spain
Cruz, EC:
Hosp Ramon & Cajal, Hematol Dept, Madrid, Spain
Martínez-Martínez, R:
Univ Seville, Spanish Natl Res Council, Hematol Dept, Inst Biomed Sevilla,Hosp Univ Virgen del Rocio, Seville, Spain
Bargay, J:
Hosp Clin San Carlos, Hematol Dept, Madrid, Spain
Balari, AS:
Hosp Univ Son Llatzer, Balearic Isl Inst Hlth Res, Hematol Dept, Palma De Mallorca, Spain
de la Rubia, J:
Hosp Duran I Reynals, Inst Catala Oncol, Hematol Dept, Lhospitalet De Llobregat, Spain
García, MTH:
Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain
Univ Catolica Valencia, Valencia, Spain
Cabañas, V:
Hosp Univ Canarias, Hematol Dept, San Cristobal la Laguna, Spain
Montero, FC:
Univ Murcia, Hosp Clin Univ Virgen de la Arrixaca, Hematol Dept, Inst Murciano Invest Biosanitaria,Pascual Parrilla, Murcia, Spain
Bernal, LP:
HM Hosp Madrid, Hematol Dept, Madrid, Spain
Montes, YG:
Hosp Clin Univ Lozano Blesa, Hematol Dept, Zaragoza, Spain
Martínez-Lopez, J:
Inst Catalan Oncol Girona, Hematol Dept, Girona, Spain
Rodriguez-Otero, P:
Univ Complutense, Hosp Univ 12 Octubre, Natl Canc Res Ctr, Hematol Dept, Madrid, Spain
Krisnik, I:
Univ Navarra, Hematol Dept, Canc Ctr Clin, Pamplona, Spain
Arguiñano, JM:
Hosp Univ Puerta de Hierro, Hematol Dept, Majadahonda, Spain
García, MEG:
Hosp Univ Navarra, Hematol Dept, Pamplona, Spain
Ocio, EM:
Hosp Univ Cabuenes, Hematol Dept, Gijon, Spain
de la Cruz, J:
Univ Cantabria, Hosp Univ Marques de Valdecilla, Valdecilla Hlth Res Inst, Hematol Dept, Santander, Spain
Mateos, MV:
Hosp Univ 12 Octubre, Res Inst i 12, Clin Res Platform PiC 12, Madrid, Spain
Rosiñol, L:
Univ Salamanca, Consejo Super Invest Cient,Ctr Biomed Res Canc Net, Inst Biol Mol & Celular Canc,Hematol Dept, Inst Invest Biomed Salamanca,Hosp Univ Salamanca, Salamanca, Spain
Bladé, J:
Univ Salamanca, Consejo Super Invest Cient,Ctr Biomed Res Canc Net, Inst Biol Mol & Celular Canc,Hematol Dept, Inst Invest Biomed Salamanca,Hosp Univ Salamanca, Salamanca, Spain
|